Biotoscana Investments SA (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced its financial results for 2018 on Friday.
The company reported an increase in net revenue for 2018 of 10% in constant currency, positively impacted by its Dosa drug, marking BRL821m.
The firm posted net income at BRL63m in 2018 compared with BRL17m in 2017.
Gross profit increased by 12% vs 2017, in constant currency.
Gross margin of 51% (including hyperinflation adjustments) vs 54% in 2017.
OPEX are in line with 34% of net revenues in 2018.
(1USD=4BRL)
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025
Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio
Perrigo to divest Dermacosmetics business for up to EUR327m
CVS Health declares quarterly dividend USD0.665 per share
Lilly declares dividend of USD1.50 for Q3
Bavarian Nordic sells US Priority Review Voucher for USD160m